Taken together, our study demonstrates that USP39 serves as an oncogenic factor in ESCC through promoting tumor proliferation in vivo and in vitro, improving invasion and migration of cancer cells and inhibiting the cell apoptosis with the treatment of DDP. This evidence concerns the gene USP39 and cancer.